Overview of AMA #85: Medications and Supplements
In this sneak peek of The Drive AMA #85, Peter Attia lays out a decision-making framework for evaluating medications and supplements. Rather than asking whether something is simply “good” or “bad,” he argues that the real question is whether a specific intervention makes sense for a specific person with a specific problem. The episode focuses on how to define the problem clearly, classify what job the intervention is supposed to do, choose the right evidence threshold, and avoid fooling yourself with vague goals or weak signals of benefit.
Core Framework: Start With the Problem, Not the Pill
Attia emphasizes that most people begin with the molecule or supplement and work backward, which is usually the wrong approach.
Define the problem in actionable terms
A useful problem definition should include:
- A measurable metric
- A target threshold
- A time horizon
Examples:
- Instead of “my cholesterol is bad,” say:
“My ApoB is 130 mg/dL, and I want it below 60 within six months.” - Instead of “my sleep is bad,” say:
“It takes me 60 minutes to fall asleep four or five nights per week, and I want that under 10 minutes within two months.”
Ask what happens if you do nothing
A real problem should have a meaningful counterfactual:
- Does it raise disease risk?
- Does it reduce quality of life?
- Does it create downstream harms?
Without this clarity, almost anything can seem helpful because vague problems are easy to “improve” accidentally.
How to Classify the Job of an Intervention
Attia breaks interventions into four broad categories:
1. Disease treatment
- Highest evidentiary bar
- More tolerance for downside because the underlying condition is serious
- Best supported by hard outcome trials or strong surrogate markers
2. Symptom relief
- Focused on how the person feels or functions
- Some placebo/noise tolerance may be acceptable if the downside is low
- Subjective benefit matters, but safety still counts
3. Risk reduction
- Usually involves problems you cannot feel directly
- Requires strong evidence, ideally hard outcomes or validated surrogate markers
- Not all biomarkers are equally meaningful
4. Optimization
- Lowest certainty, highest risk of self-deception
- Common in longevity and wellness claims
- Usually built on mechanistic reasoning rather than strong outcome data
Evidence Thresholds and Common Mistakes
Attia warns that people often confuse different tiers of evidence.
Stronger evidence is needed when:
- The goal is prevention or risk reduction
- The problem is not directly observable
- The expected effect is small
- The claim is mostly mechanistic
Mechanism is not enough
A plausible mechanism does not prove a real-world benefit. Attia highlights the danger of assuming that because something sounds biologically sensible, it must work.
Validated surrogates matter
He notes that some biomarkers are meaningful surrogates, while others are not. For example:
- ApoB is a well-validated surrogate for cardiovascular risk
- Vague “detox” or inflammatory claims are much less trustworthy
Risk Is More Than Side Effects
Attia broadens the idea of downside beyond classic adverse effects.
Real costs include:
- Side effects
- Financial cost
- Hassle and adherence burden
- Opportunity cost
- The risk of taking something unnecessary for years
He stresses that the less concrete the problem, the less downside you should be willing to accept.
How to Know Whether a Supplement Is Working
A major theme is how easy it is to fool yourself.
To judge whether something works, you need:
- A clear baseline
- A specific measurable outcome
- A realistic timeline
- A way to separate real change from noise, placebo, or random variation
Without this, people often interpret small fluctuations as proof of benefit.
Why Supplements Deserve Extra Skepticism
Attia says supplements, in particular, deserve more skepticism than they usually get because:
- They are often marketed with weak evidence
- They are frequently framed as optimization rather than treatment
- Their effects are often subtle or unmeasurable
- People tend to continue them indefinitely without clear proof of benefit
Key Takeaways
- Don’t start with the product; start with the problem.
- Define the metric, threshold, and timeline before intervening.
- Match the evidence bar to the job of the intervention.
- Be especially skeptical of optimization claims.
- Account for all forms of downside, not just side effects.
- Use validated markers and hard outcomes when possible.
- Be cautious about supplements, which are often easier to believe in than they are to justify.
What the Full AMA Promises to Cover
The full episode is said to go further into:
- How to distinguish strong vs. weak evidence
- Why baseline risk changes decision-making
- How relative risk can mislead
- How to think about stopping an intervention
- How to assess whether a supplement is actually doing anything
- The short list of over-the-counter supplements Attia thinks may be worth the trade-off